Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 28, 2013 | Post-IPO Equity | $25M | 1 | AstraZeneca | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
AstraZeneca | Yes | Post-IPO Equity |